Tag Archives: BAYZF

Top 5 Heal Care Stocks To Buy For 2019

Profire Energy (NASDAQ:PFIE)‘s stock had its “buy” rating restated by equities researchers at Maxim Group in a research report issued to clients and investors on Friday. They currently have a $7.00 price target on the oil and gas company’s stock. Maxim Group’s price target would suggest a potential upside of 114.07% from the stock’s previous close.

The analysts wrote, “Wednesday, after market close, PFIE announced 2Q18 results with revenue of $11.3 million, slightly above our estimate of $11.2 million, and EPS of $0.03, inline with our estimate of $0.03. We expect further penetration of PF3100 BMS systems in 2019 as the company recently received its Safety Integrity Level (SIL) certification and plans to expand its PF3100 sales force. We recognize additional opportunities for continued success internationally (MENA) and potential M&A activities in North America. We reiterate our Buy rating and $7 Price Target, which is based on a 10-year DCF and supported by a comparable company analysis.””

Top 5 Heal Care Stocks To Buy For 2019: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    For the third quarter, the company reported cash and equivalents of $470.4 million, while net income came in at $50 million (includes a gain of $78.7 million from the Immunomedics’ warrant). Without the one-time gain, its loss of $28.7 million would still be an improvement over net loss of $31.8 million for the same quarter last year. For the fourth quarter, the company is guiding for ADCETRIS sales in the range of $82 million to $84 million (total revenue of $128 million to $130 million). In addition to the growing opportunity for ADCETRIS (peak sales in excess of $1 billion) and the intriguing prospects of tucatinib, the company has a promising pipeline of ADC candidates and immuno-oncology assets. Partnered programs with the likes of AbbVie (NYSE:ABBV), Astellas (OTCPK:ALPMY), Genmab (OTCPK:GMXAY), Bayer (OTCPK:BAYZF), Genentech and many more also lend additional credibility to the story.

  • [By ]

    As of December 2017, Greenlight Re’s major (10%+) long positions were General Motors (GM), Brighthouse Financial (BHF), gold (GLD), Bayer (OTCPK:BAYZF), and Mylan (MYL). It also holds a long position in Micron (MU), which was the best positive contributor to its portfolio in the first quarter of 2018. These long positions were balanced by shorts in Tesla (TSLA), Netflix (NFLX), and other “bubble basket” stocks. The portfolio is also short Assured Guaranty (AGO), a municipal bond insurer, a position which is hedged by a simultaneous long in Puerto Rican debt. Overall, the portfolio is 93% gross long and 65% gross short. Unlike most insurance portfolios, just 0.5% of investments are in debt instruments and, in fact, Greenlight Re’s short portfolio was 11% allocated to sovereign debt.

Top 5 Heal Care Stocks To Buy For 2019: Royal Gold Inc.(RGLD)

Advisors’ Opinion:

  • [By Keith Noonan, Leo Sun, and Maxx Chatsko]

    In this roundtable, three Motley Fool investors have identified stocks that they believe have underappreciated strengths and tremendous long-term potential. Read on to see why they think Weibo (NASDAQ:WB), iQiyi (NASDAQ:IQ), and Royal Gold (NASDAQ:RGLD) are top stocks for growth-seeking investors.

  • [By Tyler Crowe, Matthew Frankel, CFP, and Neha Chamaria]

    So we asked three Motley Fool contributors to tell us about one of their favorite mid-cap stocks out there today. Here’s why they picked real estate investment trust (REIT) Physicians Realty Trust (NYSE:DOC), precious metal streaming company Royal Gold (NASDAQ:RGLD), and solar power component supplier SolarEdge Technologies (NASDAQ:SEDG). 

  • [By Reuben Gregg Brewer]

    Franco-Nevada Corporation’s (NYSE:FNV) stock was down roughly 11% year to date through the end of May. That’s not great, but it’s even worse when you consider that streaming and royalty peer Royal Gold Inc. (NASDAQ:RGLD) is up 9% over the same span. Even silver-heavy Wheaton Precious Metals (NYSE:WPM) has been doing better, down only about 1% (silver hasn’t performed as well gold in recent years). Why exactly is Franco-Nevada lagging its peers so badly?

Top 5 Heal Care Stocks To Buy For 2019: VSE Corporation(VSEC)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    Caterpillar Inc. (NYSE: CAT) will increase its dividend forward yield by 10.26%, VSE Corp. (Nasdaq: VSEC) will increase its dividend payout by 14.29%, and PNC Financial Services Group Inc. (NYSE: PNC) will increase its dividend payout by 26.67%.

  • [By Logan Wallace]

    Stantec (NYSE: STN) and VSE (NASDAQ:VSEC) are both business services companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

  • [By Tyler Crowe, Rich Smith, and Daniel Miller]

    In the spirit of Lynch’s investment principles, we asked three of our Motley Fool investors to each highlight a stock Wall Street isn’t paying much attention to, but could be a great investment. Here’s a brief look at their selections: WD-40 Company (NASDAQ:WDFC), Control4 (NASDAQ:CTRL), and VSE Corporation (NASDAQ:VSEC). 

Top 5 Heal Care Stocks To Buy For 2019: Volkswagen Aktiengesellschaft (VLKAY)

Advisors’ Opinion:

  • [By Max Byerly]

    Shares of Volkswagen Group (OTCMKTS:VLKAY) have been given an average rating of “Buy” by the nine research firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company.

  • [By John Rosevear]

    Volkswagen AG’s (NASDAQOTH:VLKAY) U.S. unit is teaming up with four suppliers, including chip powerhouse NVIDIA (NASDAQ:NVDA), to deal with a key technical challenge facing developers of self-driving cars: moving all the data around inside the car.

  • [By ]

    For example, FCA was the first to throw in the towel on “cars.” Ford is now following. Lately, brands such as Chevrolet (NYSE:GM), Toyota (NYSE:TM), Volkswagen (OTCPK:VLKAY) and Nissan (OTCPK:NSANY) have professed their enduring commitment to sedans and similar “cars.” That’s probably true – at least directionally. Still, even those automakers will need to prune at least a little bit in their car/sedan portfolios over the next generational cycle, 5-10 years at the most. But the point is that they say they will not take as big of an axe to those offerings in the U.S. market, as FCA and Ford just did.

  • [By ]

    Volkswagen AG (VLKAY) led the Dax higher, gaining 1.02% to €178.82, after the German carmaker reshuffled its top management, naming former BMW AG (BMWYY) executive Herbert Diess as CEO, replacing Matthias Mueller, in the company’s biggest management change since the diesel emissions scandal in 2015.

  • [By John Rosevear]

    Volkswagen AG (NASDAQOTH:VLKAY) said that its second-quarter net profit increased 6.8% to 3.31 billion euros ($3.85 billion) — despite a one-time charge of 1.6 billion euros related to the company’s 2015 diesel-emissions cheating scandal.

Top 5 Heal Care Stocks To Buy For 2019: ATA Inc.(ATAI)

Advisors’ Opinion:

  • [By Paul Ausick]

    ATA Inc. (NASDAQ: ATAI) traded down about 14% Monday to set a new 52-week low of $0.82, based on revalued shares that closed at $0.72 on Friday but traded up about 250% on Monday at $2.53. Volume was more than 200 times the daily average of around 42,000. You’re on your own here to figure this one out.

Top 5 Low Price Stocks To Own For 2018

Main thesis

I believe that Tuesday Morning (NASDAQ: TUES) is a potential turnaround situation with high upside and limited downside.

Business

According to their 10k,

We are a true closeout retailer, selling high-quality products at prices below those found in boutique, specialty and department stores. Our customers come to us for an ever-changing, exceptional assortment of brand names at great prices. Basically, they purchase items at a very low price from different sources and they sell it below retail.

What makes it interesting

Niche that is likely to be undisturbed by the ecommerce disruption right now Little debt ($30 million from accessing credit facility) with continued access to capital markets Increasing revenue despite industry headwinds, which means that the problem is likely to be internal. Insider buy in Concrete turnaround plan that could work (some of them are already working)

What I think the rest of the market missed

Only 1 analyst covering (according to yahoo finance) Niche presence in a market filled with big names Overall decrease in interest in the traditional brick and mortar retail sector Boring niche with little or no growth

Notable statistics

Top 5 Low Price Stocks To Own For 2018: Sonic Automotive Inc.(SAH)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Armour Residential REIT Inc. (NYSE: ARR), Ducommun Inc. (NYSE: DCO), PJT Partners Inc. (NYSE; PJT), Sonic Automotive Inc. (NYSE: SAH)and Tandy Leather Factory Inc. (NASDAQ: TLF).

Top 5 Low Price Stocks To Own For 2018: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    For the third quarter, the company reported cash and equivalents of $470.4 million, while net income came in at $50 million (includes a gain of $78.7 million from the Immunomedics’ warrant). Without the one-time gain, its loss of $28.7 million would still be an improvement over net loss of $31.8 million for the same quarter last year. For the fourth quarter, the company is guiding for ADCETRIS sales in the range of $82 million to $84 million (total revenue of $128 million to $130 million). In addition to the growing opportunity for ADCETRIS (peak sales in excess of $1 billion) and the intriguing prospects of tucatinib, the company has a promising pipeline of ADC candidates and immuno-oncology assets. Partnered programs with the likes of AbbVie (NYSE:ABBV), Astellas (OTCPK:ALPMY), Genmab (OTCPK:GMXAY), Bayer (OTCPK:BAYZF), Genentech and many more also lend additional credibility to the story.

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

  • [By SEEKINGALPHA.COM]

    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

Top 5 Low Price Stocks To Own For 2018: Westinghouse Air Brake Technologies Corporation(WAB)

Advisors’ Opinion:

  • [By Lee Samaha]

    On a more positive note, Flannery appears to be making ground on some key long-term objectives.

    Management feels “good” about the ability of the healthcare segment to outperform, according to Miller. Flannery claimed GE was in “active discussions” on some aviation platforms, current & lighting and distributed power, while an announcement on the divestment of transportation (rumored to be a target of Wabtec (NYSE:WAB)) is expected by the end of the second quarter. Structural cost reductions are now expected to be above the $2 billion target outlined on the investor day presentation in November 2017. Flannery outlined that he would lead the creation of a new operating system for GE based on “lean, six sigma ad agile” involving “continuous improvement and customer experience.”

    As a reminder, GE has promised $20 billion of asset sales, and the commentary on the earnings call was reassuring, particularly as the first deal (healthcare IT assets) was underwhelming.

  • [By WWW.MONEYSHOW.COM]

    Westinghouse Air Brake Technologies Corporation (WAB) scores highly based on my Warren Buffett-based model, which is based on the book Buffettology, and also the Peter Lynch-inspired approach that uses the method outlined by Lynch in One Up on Wall Street.

  • [By Joseph Griffin]

    Mountain Pacific Investment Advisers Inc. ID cut its holdings in Wabtec Co. (NYSE:WAB) by 1.2% during the first quarter, HoldingsChannel.com reports. The firm owned 226,515 shares of the transportation company’s stock after selling 2,800 shares during the period. Wabtec comprises 1.9% of Mountain Pacific Investment Advisers Inc. ID’s investment portfolio, making the stock its 25th biggest position. Mountain Pacific Investment Advisers Inc. ID’s holdings in Wabtec were worth $18,438,000 at the end of the most recent quarter.

  • [By Matthew DiLallo]

    Westinghouse Air Brake Technologies(NYSE:WAB), or Wabtec, is off to a solid start in 2018. The rail products company reported double-digit gains in revenue and earnings thanks to a combination of factors. As a result, the company remains on pace to hit its full-year guidance.

Top 5 Low Price Stocks To Own For 2018: Antares Pharma, Inc.(ATRS)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell 0.32 percent. Meanwhile, top losers in the sector included Antares Pharma Inc (NASDAQ: ATRS), down 38 percent, and Infinity Pharmaceuticals Inc. (NASDAQ: INFI) down 16 percent.

  • [By Logan Wallace]

    BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

Top 5 Low Price Stocks To Own For 2018: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 12% Tuesday and posted a new 52-week low of $0.29 after closing Monday at $0.33. The stock’s 52-week high is $4.46. Volume was around 5.9 million, about 8 times the daily average. The company filed Monday for Chapter 11 bankruptcy.

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 78% Monday and posted a new 52-week low of $0.31 after closing Friday at $1.40. The stock’s 52-week high is $4.46. Volume was around 7.5million, about 15 times the daily average. The company has filed for Chapter 11 bankruptcy.

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios:

  • [By Keith Speights]

    Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.